New research indicates that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end conventional diet and exercise plans.
Findings released in a leading medical journal shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"People buying such medications should be cognizant of the danger of fast rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to original weight within about 18 months.
Analyzing Approaches
The analysis, which reviewed dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
The team note that people who lose weight through lifestyle changes alone usually have a more gradual weight regain—around 0.1 kg a month—once they finish.
Explaining the Fast Regain
Experts propose the mode of action of the jabs explains the amplified weight return.
The injections imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone levels far above than normal may cause the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement results in appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Condition?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of weight regain, the treatment is often ongoing.
This view is reinforced by pharmaceutical companies, who say that the results "emphasize the long-term nature of obesity," similar to managing conditions like high blood pressure.
User Experiences
Individuals who have come off the medication describe a intense return of appetite.
"It was like a switch flipping and you're instantly ravenous," said a patient.
This difficulty is worsened if individuals have not established lasting dietary or behavioural changes during treatment.
Significant Interest
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is greater among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and long-term success relies on combined lifestyle support.